Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4359921 | 0.93 | — | — | |
| SCHEMBL13675404 | 0.71 | — | — | |
| SCHEMBL16866784 | 0.71 | — | — | |
| SCHEMBL13575584 | 0.71 | SUV39H2 (0.30) | — | |
| SCHEMBL25775999 | 0.69 | — | — | |
| SCHEMBL15536892 | 0.65 | FDPS (0.33) | CA2 | |
| Obi-2660 SCHEMBL12597913 | 0.65 | — | — | |
| SCHEMBL3392230 | 0.65 | FDPS (0.33) | CA2 | |
| SCHEMBL654555 | 0.65 | — | — | |
| Phosphoric Acid Monomethyl Ester SCHEMBL19942 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719498-A1 | RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| EP-4719486-A1 | CONJUGATES AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| EP-4646235-A1 | ALPHA-EMITTING RADIONUCLIDES FOR USE IN THE TREATMENT OF PERITONEAL CANCER | Oncoinvent AS (NO) | 2025-11-12 | — | — | EP | claimed |
| WO-2025199636-A1 | TARGETED RADIOLIGAND COMPOUNDS AND USES THEREOF | MCMASTER UNIVERSITY (CA) | 2025-10-02 | — | — | WO | claimed |
| EP-4619411-A1 | DUAL RECEPTOR TARGETING RADIOLIGANDS AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2025-09-24 | — | — | EP | claimed |
| CN-120129690-A | Dual receptor targeted radioligands and uses thereof | 辐联科技香港有限公司 | 2025-06-10 | — | — | CN | claimed |
| WO-2024245407-A1 | CONJUGATES AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-12-05 | — | — | WO | claimed |
| WO-2024245421-A1 | RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-12-05 | — | — | WO | claimed |
| WO-2024146921-A1 | ALPHA-EMITTING RADIONUCLIDES FOR USE IN THE TREATMENT OF PERITONEAL CANCER | ONCOINVENT AS (NO) | 2024-07-11 | — | — | WO | claimed |
| WO-2024083224-A1 | DUAL RECEPTOR TARGETING RADIOLIGANDS AND USES THEREOF RELATED APPLICATIONS | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-04-25 | — | — | WO | claimed |
| EP-4719486-A1 | CONJUGATES AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4719498-A1 | RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4646235-A1 | ALPHA-EMITTING RADIONUCLIDES FOR USE IN THE TREATMENT OF PERITONEAL CANCER | Oncoinvent AS (NO) | 2025-11-12 | — | — | EP | disclosed |
| WO-2025199636-A1 | TARGETED RADIOLIGAND COMPOUNDS AND USES THEREOF | MCMASTER UNIVERSITY (CA) | 2025-10-02 | — | — | WO | disclosed |
| EP-4619411-A1 | DUAL RECEPTOR TARGETING RADIOLIGANDS AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2025-09-24 | — | — | EP | disclosed |
| US-20230330280-A1 | PREPARATIONS OF RADIUM-224 AND PROGENIES FOR USE IN RADIONUCLIDE THERAPY IN COMBINATION WITH DNA REPAIR INHIBITORS | Oncoinvent Solutions AS (NO) | 2023-10-19 | — | — | US | disclosed |
| EP-4213826-A1 | PREPARATIONS OF RADIUM-224 AND PROGENIES FOR USE IN RADIONUCLIDE THERAPY IN COMBINATION WITH DNA REPAIR INHIBITORS | Oncoinvent AS (NO) | 2023-07-26 | — | — | EP | disclosed |
| EP-4213893-A1 | SIZE CONTROLLED RADIOLABELLED PARTICLES | Oncoinvent AS (NO) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022058337-A1 | SIZE CONTROLLED RADIOLABELLED PARTICLES | ONCOINVENT AS (NO) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022058338-A1 | PREPARATIONS OF RADIUM-224 AND PROGENIES FOR USE IN RADIONUCLIDE THERAPY IN COMBINATION WITH DNA REPAIR INHIBITORS | ONCOINVENT AS (NO) | 2022-03-24 | — | — | WO | disclosed |